Tags · Access
personal import
Rules on importing for personal use, which vary enormously.
Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · compounding · shortage · NHS · EMA · FDA · MHRA · telehealth
52 topics · page 1 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…
|
2 | 22k | 1h | |
|
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. Asking about prescription portability between countries directly, because I have read four…
|
+104 | 114 | 6.1k | 3h |
|
Private prescribing in the UK: what is actually involved
On the subject in the title: Private prescribing in the UK: what is actually involved Working notes rather than a conclusion. The question about private prescribing that I actually want answered is the second…
|
+66 | 76 | 46k | 14h |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says, since the…
|
+8 | 12 | 15k | 17h |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting a stated criterion rather than an outcome,…
|
+37 | 42 | 2.1k | 1d |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
Follow-up: How compounding permissions changed when supply normalised
How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…
|
+72 | 77 | 1.5k | 1d |
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Irish differences is wrong? I ask…
|
+8 | 12 | 782 | 1d |
|
NHS criteria and how they are applied in practice
NHS criteria and how they are applied in practice — setting out what I have, and where I think it stops being reliable. I was wrong about NHS criteria in a thread last spring and I would like to correct it…
|
+37 | 42 | 31k | 2d |
|
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Regional question, dated March 2026, because everything in this category expires. The position differs…
|
+10 | 14 | 27k | 2d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…
|
2 | 1.8k | 2mo | |
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Personal import allowances. It is mine, it is…
|
+124 | 132 | 9.2k | 2mo |
|
EU-wide position versus national implementation — what changed since
EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of eu-wide position…
|
+22 | 26 | 58k | 2mo |
|
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
|
+7 | 11 | 39k | 3mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about compound…
|
+72 | 78 | 23k | 3mo |
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
|
Pharmacy supply in the UK and the questions you will be asked
On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. Asking about pharmacy supply on behalf of the question I keep seeing asked…
|
+95 | 105 | 1.3k | 4mo |
|
[2026 update] Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+40 | 45 | 14k | 4mo |
|
Reading a regulatory notice rather than an article about it
Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Posting a small dataset on reading a regulatory notice. It is…
|
2 | 2.9k | 5mo | |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Asking about Language barriers in accessing on behalf of…
|
+131 | 148 | 28k | 5mo |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…
|
+100 | 110 | 37k | 5mo |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
Availability by country, dated, with primary sources — one year on
Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+7 | 11 | 850 | 7mo |
|
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…
|
+22 | 26 | 53k | 7mo |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. I have spent a fortnight trying to pin personal import allowances down and I want to set out where I…
|
+5 | 9 | 3.2k | 7mo |
|
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. The question about cross-border purchase rules within that I actually want answered is the second…
|
+45 | 49 | 15k | 8mo |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
|
+70 | 74 | 7k | 8mo |